
## Lisa Moris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3892016/publications.pdf Version: 2024-02-01



LISA MODIS

#	Article	IF	CITATIONS
1	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	1.9	1,545
2	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part Il—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	1.9	633
3	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. European Urology, 2019, 75, 967-987.	1.9	278
4	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	1.9	151
5	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus, 2020, 6, 231-234.	3.1	131
6	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. European Urology, 2020, 77, 614-627.	1.9	101
7	Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. European Urology Oncology, 2019, 2, 174-188.	5.4	58
8	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports, 2019, 9, 13786.	3.3	44
9	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nature Reviews Urology, 2021, 18, 739-762.	3.8	38
10	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. European Urology, 2022, 81, 337-346.	1.9	33
11	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. European Urology Oncology, 2021, 4, 405-423.	5.4	26
12	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. World Journal of Urology, 2019, 37, 1857-1866.	2.2	23
13	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 674-689.	3.1	21
14	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2021, 80, 531-545.	1.9	21
15	The androgen receptor depends on ligandâ€binding domain dimerization for transcriptional activation. EMBO Reports, 2021, 22, e52764.	4.5	20
16	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	1.4	19
17	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. European Urology Oncology, 2019, 2, 589-596.	5.4	19
18	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. World Journal of Urology, 2019, 37, 1543-1549.	2.2	19

LISA MORIS

#	Article	IF	CITATIONS
19	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer, 2018, 18, 354.	2.6	16
20	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. Translational Andrology and Urology, 2020, 9, 2541-2554.	1.4	15
21	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. Cells, 2020, 9, 2494.	4.1	13
22	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. European Urology, 2022, 81, 503-514.	1.9	13
23	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. Frontiers in Oncology, 2020, 10, 246.	2.8	11
24	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. SpringerPlus, 2016, 5, 646.	1.2	10
25	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non–Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. European Urology Focus, 2022, 8, 690-700.	3.1	10
26	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. Frontiers in Oncology, 2017, 7, 280.	2.8	9
27	Tumor Volume and Clinical Failure in Highâ€Risk Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 3-9.	2.3	8
28	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. European Urology, 2019, 75, 699-702.	1.9	8
29	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. Frontiers in Oncology, 2019, 9, 781.	2.8	7
30	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancerâ€specific survival after radical cystectomy: external validation in a large biâ€institutional cohort. BJU International, 2020, 126, 704-714.	2.5	7
31	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precision Oncology, 2022, 6, e2100543.	3.0	7
32	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	3.1	6
33	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. World Journal of Urology, 2021, 39, 399-406.	2.2	4
34	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	1.9	4
35	The influence of steroid metabolism on CYP17A1 inhibitor activity. Nature Reviews Urology, 2017, 14, 590-592.	3.8	3
36	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	2.4	3

LISA MORIS

#	Article	IF	CITATIONS
37	Small-molecule profiling for steroid receptor activity using a universal steroid receptor reporter assay. Journal of Steroid Biochemistry and Molecular Biology, 2022, 217, 106043.	2.5	3
38	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. Molecular Cancer Research, 2022, 20, 527-541.	3.4	3
39	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020:77:614–27. European Urology. 2020. 78. e120-e121.	1.9	2
40	Prognostic score predicts overall survival following complete urinary tract extirpation. Scandinavian Journal of Urology, 2020, 54, 70-79.	1.0	2
41	Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review, Eur Urol 2020:77:614–27. European Urology, 2020, 78. e193-e194.	1.9	1
42	Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614–27. European Urology, 2020, 78, e116-e117.	1.9	0